RecruitingNot ApplicableNCT05865119

OPTImal Treatment of Sinus VENOSUS Defect

OPTImal Treatment of Sinus VENOSUS Defect - Efficacy and Safety of Transcatheter Correction Compared to Surgical Treatment in Patients With Sinus Venosus Defect


Sponsor

Centre Chirurgical Marie Lannelongue

Enrollment

60 participants

Start Date

May 12, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option. The procedure involves placement of a covered stent in the superior vena cava that tunnels the anomalous pulmonary venous return to the left atrium. Preliminary results are limited but promising. The devices to be used depend on anatomic considerations. XXL stents than 70mm are often required. Today, the availability of CE marked stents is limited. There have been recent reports of successful corrections with the specifically developed Optimus XXL 100mm covered stent (ANDRATEC) with compassionate approval from the Agence Nationale de Sûreté du Médicament in France. Setting up a feasibility study to investigate the use of medical devices in this indication was required. The objective of this project is to study the feasibility, efficacy and safety of the Optimus stent in this newly developed transcatheter procedure, in comparison with the gold-standard surgical method. A French national multicenter comparative cohort study including all eligible patients referred for transcatheter correction of SVD was designed. The feasibility of the transcatheter procedures will be investigated beforehand by virtual digital simulation and simulation on a 3D printed model. The procedures will then be performed in centers of the M3C network for complex congenital heart diseases (CARDIOGEN). The primary endpoint will be a composite of efficacy, defined as complete occlusion of the shunt, and safety, defined as the absence of major events at 6 months. The secondary endpoints will be anatomical, functional and psychosocial (quality of life). It is expected that transcatheter treatment gives comparable results to surgery on the primary endpoint. This could justify the further development of this procedure as an alternative to surgery and facilitate the validation of dedicated equipment.


Eligibility

Min Age: 12 Years

Inclusion Criteria7

  • from 12 years of age
  • SVD with right ventricular end-diastolic volume dilatation (RV EDV) on imaging (echocardiography and/or MRI), defined by the guidelines as RV EDV greater than 112mL/m2 for women and 121 mL/m2 for men.
  • With an indication for atrial septal defect correction, indicated at a medical-surgical meeting according to the ESC 2020 guideline criteria
  • Adult patients who received informed information about the study and signed a consent to participate in the study
  • Minor patients, no opposition from both holders of parental authority to data processing.
  • Patient agreeing to be followed for the duration of the study
  • Affiliated or beneficiary of a social security plan NB: Minor patients will only be considered eligible for the surgical procedure and will be studied descriptively.

Exclusion Criteria5

  • Patient under guardianship or curatorship
  • Patient deprived of liberty
  • Patient under judicial protection
  • Pregnant or breastfeeding woman
  • Patient already included in an interventional research protocol

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEOPTIMUS covered stent

The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.

PROCEDURESurgical correction of a SVD

Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques


Locations(13)

CHU Bordeaux

Bordeaux, France

Hospices Civils de Lyon

Bron, France

CHU Clermont-Ferrand

Clermont-Ferrand, France

CHU Grenoble

Grenoble, France

Sébastien HASCOËT

Le Plessis-Robinson, France

CHU Lille

Lille, France

Hôpitaux universitaire de Marseille

Marseille, France

CHU Nantes

Nantes, France

CHU Necker APHP Paris

Paris, France

HEGP Paris

Paris, France

CHU Toulouse

Toulouse, France

Clinique Pasteur, Toulouse

Toulouse, France

CHU Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05865119


Related Trials